In this post, we will be taking a closer look at some of the most popular pharmacy-related articles recently published across medical journals.

ASHP and ASHP Foundation Pharmacy Forecast 2025: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems

  • American Journal of Health-System Pharmacy : AJHP
  • January 2025
  • The 2025 ASHP Pharmacy Forecast report has been meticulously crafted to pinpoint and analyze the emerging trends that are poised to shape the landscape of healthcare, health systems, and the pharmacy profession. This comprehensive report offers invaluable insights and recommendations to guide strategic planning efforts, urging pharmacists and health-system leaders to take proactive steps in response to these evolving trends.
  • Abstract
  • Full Text

Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022

  • Journal of the American Pharmacists Association : JAPhA
  • January 2025
  • The recent approvals by the Food and Drug Administration of glucagon-like peptide 1 (GLP-1) receptor agonists associated with significant weight loss have sparked curiosity regarding demand projections. The objective of the study was to assess the frequency of GLP-1 receptor agonist product usage among individuals with type 2 diabetes (T2D), cardiovascular disease (CVD), and overweight or obese status. A secondary objective was to estimate the monthly growth rate of each product since its introduction at the University of California Health.
  • Abstract
  • Full Text

Validity in Question: Is Pharmacy Education’s Research Meeting the Standards?

  • American Journal of Pharmaceutical Education
  • December 2024
  • Examine the frequency of validity evidence reporting in educational testing as documented in pharmacy education literature and assess any trends over a span of ten years. Despite the crucial importance of validity evidence in guaranteeing the accurate interpretation of educational testing results, its reporting within pharmacy education literature has shown inconsistency and a noticeable decrease over the past decade. The absence of validity evidence undermines the credibility and significance of research findings, as accurate test score interpretation relies heavily on this essential component.
  • Full Text

Ensuring glucagon access for people with diabetes: A case example from community pharmacy

  • Journal of the American College of Clinical Pharmacy
  • January 2025
  • Community pharmacy teams have the ability to identify individuals who are at high risk for hypoglycemia and can play a crucial role in enhancing access to glucagon. By utilizing the Community Pharmacy Enhanced Services Network (CPESN®) USA as a framework, we will outline the various opportunities available for community pharmacies to enhance access to glucagon and ultimately improve patient health outcomes.
  • Full Text

Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States

  • Journal of Managed Care & Specialty Pharmacy
  • December 2024
  • Immune thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening condition characterized by thrombotic microangiopathy. Caplacizumab has been approved by both the European Medicines Agency and the US Food and Drug Administration as the sole treatment for iTTP. It is administered in conjunction with plasma exchange therapy (PEX) and immunosuppression (IS). The National Institute for Health and Care Excellence's independent appraisal committee conducted a cost-effectiveness evaluation of caplacizumab. Their assessment determined that the addition of caplacizumab to PEX and IS is a cost-effective treatment option for iTTP patients in the United Kingdom, particularly when implemented under a patient access scheme.
  • Abstract
  • Full Text

Impact of Apixaban Lead-In Therapy Duration After Parenteral Anticoagulation on Bleeding in Patients Treated for Venous Thromboembolism

  • Journal of Pharmacy Practice
  • January 2025
  • This retrospective cohort study focused on adult patients admitted to the Veterans Affairs Health Care System between January 2011 and April 2022. The study specifically looked at patients who had received at least 24 hours of parenteral anticoagulation followed by lead-in apixaban therapy for the treatment of VTE. The findings of this study shed light on the real-world application of lead-in apixaban therapy in patients with VTE, particularly in those who have received prior anticoagulation treatment or are at an increased risk of bleeding. Understanding how clinicians approach the duration of lead-in therapy in these cases can help optimize treatment strategies and improve patient outcomes.
  • Abstract
  • Full Text

A Cost Analysis of Opioid/Acetaminophen Therapy Versus a Multidrug, Opioid-Free Multimodal Postoperative Pain Control Regimen

  • Hospital Pharmacy 
  • December 2024
  • The aim of this study was to conduct a cost analysis of postoperative pain management methods following orthopaedic surgery, specifically comparing the expenses associated with opioid/acetaminophen therapy versus an opioid-free, multidrug, multimodal pathway. This research constitutes a secondary examination of data obtained from two IRB-approved prospective studies that investigated pain management strategies following elective orthopaedic procedures at a single medical facility.
  • Abstract
  • Full Text

There you have it - a look at some of the most popular pharmacy articles recently released. Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, All Rights Reserved.